Maximum quantity allowed is 999
Please select the quantity
CAS RN: 103060-53-3 | Product Number: D4229
Daptomycin
Purity: >94.0%(HPLC)(N)
Synonyms:
Product Documents:
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
Product Number | D4229 |
Purity / Analysis Method | >94.0%(HPLC)(N) |
Molecular Formula / Molecular Weight | C__7__2H__1__0__1N__1__7O__2__6 = 1,620.69 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Frozen (-20°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 103060-53-3 |
Reaxys Registry Number | 8186242 |
PubChem Substance ID | 172089104 |
Merck Index (14) | 2823 |
MDL Number | MFCD08282794 |
Specifications
Appearance | White to Yellow to Orange powder to crystal |
Purity(HPLC) | min. 94.0 area% |
Purity(with Total Nitrogen) | min. 94.0 % |
NMR | confirm to structure |
Properties (reference)
Maximum Absorption Wavelength | 260(EtOH) nm |
Solubility (soluble in) | Methanol |
GHS
Related Laws:
RTECS# | HB5626000 |
Transport Information:
H.S.code* | 2941.90-000 |
Application
Studies on the Antibiotic Activity of Daptomycin
References
- Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
- In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
- Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
- Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
- Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.